Interpreta's Leadership Team
Ahmed Ghouri, M.D.
Founder and Chief Executive Officer
Dr. Ahmed Ghouri co-founded Interpreta in 2014 and currently serves as Interpreta’s Chief Executive Officer and as a director. Prior to founding Interpreta, Dr. Ghouri was a founder and Chief Executive Officer at Anvita, a clinical analytics company acquired by Humana in 2011. Dr. Ghouri is the principal author of 70+ peer reviewed scientific publications and lead author on eight granted US Patents in analytics, medical devices and software. He was a co-lead investigator leading to the FDA approval of new drugs Flumazenil (the first Benzodiazepine reversal drug) and Desflurane (the first ultra-rapid general anesthetic). Dr. Ghouri holds an M.D. from Washington University, School of Medicine where he also completed a biomedical engineering fellowship. He is a board-certified anesthesiologist.
Founder and Chairman of the Board
Gary Rayner co-founded Interpreta in 2014 and currently serves as Interpreta’s Chairman of the Board. Prior to founding Interpreta, Mr. Rayner was the founder and Chief Executive Officer at Lifeproof, an all-protective, everyday smartphone and tablet case company acquired by Otterbox in 2013. Prior to Lifeproof, Mr. Rayner was the VP of Business Development at Anvita. Previously, he founded DriveCam (now Lytx) and OpalTech. Mr. Rayner won E&Y Entrepreneur of the Year in San Diego in 2013 and has authored over 25 granted US patents. He holds an M.S. in Computer & Communication Systems and an MBA from Queensland University of Technology.
Founder and President
Raghu Sugavanam co-founded Interpreta in 2014 and currently serves as Interpreta’s President. Prior to founding Interpreta, Mr. Sugavanam was a founder, Chief Technology Officer and Principal Architect at Anvita, a clinical analytics company acquired by Humana in 2011. Prior to Anvita, he was a founder and President at Mercantile Software Systems, a high-performance database marketing system company acquired by Harte-Hanks in 1997. He holds an M.S. in Computer Science from Rutgers University, an M.S. in Chemical Engineering from Washington University in St. Louis, and a B.S. in Chemical Engineering from the Indian Institute of Technology in Madras.
Senior Management Team
Keith Glassford, Ph.D.
Vice President, Development Operations
Dr. Keith Glassford joined in 2016 and currently serves as Interpreta’s Vice President of Development Operations. Prior to joining Interpreta, Dr. Glassford was Vice President of Solutions Delivery for Anvita Health where he worked on population health solutions. Prior to Anvita, he served as Vice President of Client Services at CliniComp, Intl. which develops electronic medical record solutions for hospitals, integrated delivery networks, and other acute care providers. Prior to CliniComp, Dr. Glassford was Vice President of the Chemicals, Materials, & Manufacturing division for Accelrys Inc., a leading informatics and computational science company. Dr. Glassford is a seasoned scientist, healthcare, and high-tech business executive with a Ph.D. in Chemical Engineering from the University of Minnesota and 20 years of experience as a key player in the growth and profitability of enterprise healthcare and scientific informatics software and services companies.
Steve Kempf, Jr., MBA
Vice President, Client Solutions
Steve Kempf Jr. joined in 2016 and currently serves as Interpreta's Vice President of Client Solutions. Prior to joining Interpreta, Mr. Kempf was with Humana for 10 years. He was Vice President of Strategic Accounts for Anvita Health, a clinical analytics company acquired by Humana in 2011. Prior to that, he was a Director in Clinical Strategy and Technology at Humana, leading member and provider interventions for the success of Medicare and Commercial LOBs. Before Humana, Mr. Kempf worked for seven years at Norton Healthcare, Kentucky's largest healthcare delivery system, in the Cancer Center and revenue cycle operations. He was also recognized with the “Forty under 40” award from Business First in 2007. Mr. Kempf obtained a Master’s degree in Business Administration and a Bachelor’s degree in Biology from the University of Louisville.
Hatem (Tim) Sayed, M.D., MBA
Vice President, Physician Engagement
Dr. Hatem (Tim) Abou-Sayed joined Interpreta in 2015 and currently serves as Vice President, Physician Engagement. Prior to joining Interpreta, he served as Medical Director, EMA Plastic Surgery at Modernizing Medicine. Dr. Abou-Sayed is board certified in plastic surgery and general surgery, and was previously in continuous practice for over a decade in south Florida, engaged in complex reconstructive surgery and aesthetics. He completed his residencies in surgery at Massachusetts General Hospital and plastic surgery at the University of California, San Francisco (UCSF). Dr. Abou-Sayed earned his M.D. from UCSF, his MBA from the Executive MBA program at the Kellogg School of Management at Northwestern University, and a B.S. in Electrical Engineering and Computer Sciences from the University of California, Berkeley. He is licensed to practice medicine in California, Texas and Florida. He is a regular advisor to and investor in digital health, wellness and medical device ventures.
Benjamin Yu, M.D., Ph.D.
Vice President, Medical Informatics and Genomics
Dr. Benjamin Yu joined in 2014 and currently serves as Vice President, Clinical Informatics and Genomics. Prior to joining Interpreta, Dr. Yu was a faculty member of the University of California San Diego and Institute for Genomic Medicine. Dr. Yu brings his experience as a leader in human variation and genomics. His publications in Nature, Cell Stem Cell, Developmental Cell and others have received over 2000 citations, and under his leadership his laboratory received more than 10 years of funding from NIH, California Institute for Regenerative Medicine, and the Bill and Melinda Gates Foundation. Dr. Yu received his M.D., Ph.D. and residency training at Washington University. Dr. Yu is board-certified in dermatology and has been licensed to practice medicine in California since 2002. He continues to participate in training new students and residents in dermatology and genetics, and advises on San Diego's Biocom Big Data Committee.
Matt Yuill, M.D.
Vice President, Quality and Risk Analytics
Dr. Matt Yuill joined in 2015 and currently serves as Interpreta's Vice President, Quality and Risk Analytics. Dr. Yuill brings his experience as an expert in HCC risk adjustment and ICD9/10 coding. Prior to joining Interpreta, Dr. Yuill had worked as an informaticist for six years, and was among the pioneer group to become board certified in the new subspecialty of Clinical Informatics. He completed his residency in Internal Medicine and Pediatrics at Vanderbilt University and is currently board certified in Internal Medicine and in Pediatrics. Dr. Yuill holds an M.D. from the University of Kentucky. He is licensed to practice medicine in Tennessee and lives just outside of Nashville where he also works as a part-time hospitalist.